IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

WOLPE et al.

Appln. No. 08/832,443

Filed: April 3, 1997

Title: 1

Inhibitor and Stimulator of Stem Cell Proliferation and Uses Thereof

Hon. Commissioner for Patents

Washington, D.C. 20231

Sir:

Atty Dkt. 1331-222 C# M#

Group Art Unit: 1644

Examiner: M. Tung

Date: October 3, 2001

-- CEIVED

OCT 0 5 2001

JENTER 1600/2900

AMENDMENT UNDER 37 CFR § 1.111

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment 20 minus highest number previously paid for 20 (at least 20) = 0×18.00	\$	0.00
Independent claims after amendment 3 minus highest number previously paid for 3 (at least 3) = $0 \times 84.00	\$	0.00
If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)	\$	0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)	\$	0.00
Terminal disclaimer enclosed, add \$110.00 First submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00)	\$ \$	0.00
Second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00)	\$	0.00
Please enter the previously unentered , filed		
Subtotal	\$	0.00
If "small entity," then enter half (1/2) of subtotal and subtract Statement filed herewith	-\$	0.00
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$	0.00
Assignment Recording Fee (\$40.00)	\$	0.00
TOTAL FEE ENCLOSED	\$	0.00

The Commissioner is hereby authorized to charge any <u>deficiency</u> in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A <u>duplicate</u> copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000

Facsimile: (703) 816-4100

GRT:

NIXON & VANDERHYE P.C.

By Atty: Gary R. Tanigawa, Reg. No. 43180

Signature:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

120. 02. ch 1600/2900

In re Patent Application of

WOLPE et al.

Appln. No. 08/832,443

Filed: April 3, 1997

Atty. Ref.: 1331-222

Group Art Unit: 1644

Examiner: M. Tung

FOR: INHIBITOR AND STIMULATOR OF STEM CELL PROLIFERATION AND USES

OCI 0 3 200

THEREOF

AMENDMENT UNDER 37 CFR § 1.111

October 3, 2001

Hon. Commissioner for Patents Washington, DC 20231

Sir:

Responsive to the pending Office Action (Paper No. 27) mailed July 3, 2001, entry and consideration of the following amendments and remarks are respectfully requested.

IN THE CLAIMS

Kindly enter the following amended claims.

47. (2 x Amended) A method of stimulating stem cell proliferation comprising contacting hematopoietic cells with a stem cell proliferation stimulating amount of INPROL or an opiate compound or a stem cell proliferation stimulating amount of a combination of INPROL and an opiate compound,

wherein said INPROL is selected from the group consisting of the alpha chain of hemoglobin, the beta chain of hemoglobin, the gamma chain of hemoglobin, the delta chain of hemoglobin, the epsilon chain of hemoglobin, the zeta chain of hemoglobin,

a polypeptide having the sequence of amino acids 1-97 of the human alpha hemoglobin chain,

a polypeptide having the sequence of amino acids 1-94 of the human alpha ,, (Lice "... hemoglobin chain,